IGM Biosciences, Inc. provided sales guidance for full year 2022. The company estimates full year collaboration revenue of approximately $1 million related to the Sanofi agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.24 USD | -0.96% |
|
-10.40% | -12.88% |
05-09 | RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk | MT |
05-08 | Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000 | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.88% | 427M | |
+14.84% | 121B | |
+18.31% | 112B | |
+2.94% | 22.72B | |
-18.26% | 20.82B | |
-18.47% | 16.66B | |
-42.36% | 16.36B | |
-14.23% | 16.19B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- IGMS Stock
- News IGM Biosciences, Inc.
- Igm Biosciences, Inc. Provides Sales Guidance for Full Year 2022